Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
126.72
+1.90 (1.52%)
Jul 16, 2025, 4:00 PM EDT
-19.11%
Fund Assets676.00M
Expense Ratio0.80%
Min. Investment$1,000
Turnover35.87%
Dividend (ttm)11.76
Dividend Yield9.42%
Dividend Growthn/a
Payout Frequencyn/a
Ex-Dividend DateDec 20, 2024
Previous Close124.82
YTD Return-1.65%
1-Year Return-11.30%
5-Year Return-10.95%
52-Week Low104.73
52-Week High160.08
Beta (5Y)n/a
Holdings88
Inception DateSep 1, 2009

About FTDZX

Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.

Fund Family Franklin Templeton Investments
Category Health
Stock Exchange NASDAQ
Ticker Symbol FTDZX
Share Class Advisor Class
Index NASDAQ Biotechnology CR

Performance

FTDZX had a total return of -11.30% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.95%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

SymbolShare ClassExpense Ratio
FRBRXClass R60.69%
FBDIXClass A1.05%
FBTDXClass C1.80%

Top 10 Holdings

49.47% of assets
NameSymbolWeight
Gilead Sciences, Inc.GILD8.17%
Amgen Inc.AMGN7.64%
Vertex Pharmaceuticals IncorporatedVRTX7.25%
Ascendis Pharma A/SASND4.89%
Regeneron Pharmaceuticals, Inc.REGN4.34%
argenx SEARGX3.80%
Jazz Pharmaceuticals plcJAZZ3.79%
Merus N.V.MRUS3.52%
PTC Therapeutics, Inc.PTCT3.16%
Neurocrine Biosciences, Inc.NBIX2.91%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 20, 2024$11.7607Dec 20, 2024
Dec 20, 2022$0.4163Dec 20, 2022
Dec 15, 2021$18.0843Dec 15, 2021
Dec 15, 2020$10.3921Dec 15, 2020
Dec 16, 2019$14.1643Dec 18, 2019
Dec 17, 2018$4.5496Dec 19, 2018
Full Dividend History